Study: NCT05971602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)
Description: D- 300 milligram (mg) once daily (QD) for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)
Description: P- 200 mg QD for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)
Description: Fixed dose combination (FDC) of 75 mg of isoniazid, 150 mg of rifampicin, 400 mg of pyrazinamide, and 275 mg of ethambutol (HRZE) (Standard of Care \[SOC\]). All the doses administered will be weight-based.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)
Description: Fixed dose combination (FDC) of 75 mg of isoniazid, 150 mg of rifampicin, 400 mg of pyrazinamide, and 275 mg of ethambutol (HRZE) (Standard of Care \[SOC\]). All the doses administered will be weight-based.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)
Description: X - Pretomanid 200 mg QD for treatment duration OR Delamanid 300 mg QD for treatment duration; B - 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S-1200 mg QD for treatment duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)
Description: X - Pretomanid 200 mg QD for treatment duration OR Delamanid 300 mg QD for treatment duration; B - 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S-1200 mg QD for treatment duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)
Description: X - Pretomanid 200 mg QD for treatment duration OR Delamanid 300 mg QD for treatment duration; B - 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S-1200 mg QD for treatment duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)
Description: X - Pretomanid 200 mg QD for treatment duration OR Delamanid 300 mg QD for treatment duration; B - 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S-1200 mg QD for treatment duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)
Description: X - Pretomanid 200 mg QD for treatment duration OR Delamanid 300 mg QD for treatment duration; B - 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S-1200 mg QD for treatment duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)
Description: X - Pretomanid 200 mg QD for treatment duration OR Delamanid 300 mg QD for treatment duration; B - 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S-1200 mg QD for treatment duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid and Rifampicin (HR)
Description: Fixed dose combination (FDC) of 75 mg of isoniazid and 150 mg of rifampicin (HR) (Standard of Care \[SOC\]). All the doses administered will be weight-based.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid and Rifampicin (HR)
Description: Fixed dose combination (FDC) of 75 mg of isoniazid and 150 mg of rifampicin (HR) (Standard of Care \[SOC\]). All the doses administered will be weight-based.